A new triple threat to CLL
- PMID: 30309874
- DOI: 10.1182/blood-2018-08-870808
A new triple threat to CLL
Conflict of interest statement
Conflict-of-interest disclosure: M.S.D. served as a consultant or advisory board member for Genentech, Janssen Oncology, Pharmacyclics, TG Therapeutics, AbbVie, Merck, AstraZeneca, Verastem, Gilead Sciences, and Syros Pharmaceuticals; and received research funding from Genentech, Pharmacyclics, TG Therapeutics, Verastem, Bristol-Myers Squibb, Surface Oncology, and MEI Pharma. B.L.L. declares no competing financial interests.
Comment on
-
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.Blood. 2018 Oct 11;132(15):1568-1572. doi: 10.1182/blood-2018-05-853564. Epub 2018 Aug 15. Blood. 2018. PMID: 30111609 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources